Among irAEs noted during trials of PD-1 inhibitors, pneumonitis has been considered to be an “event of special interest”, occurring at a rate of around 3% and resulting in three treatment-related deaths in a phase I trial of nivolumab for NSCLC13. This evidence concerns the gene PDCD1 and pneumonitis.